cabometyx placeresult survey
come pressur follow earli approv combin
rate base cabometyx growth renal cell carcinoma rcc exhibit
set determin potenti impact cabometyx rcc survey
us oncologist conclus cabometyx use rcc current predominantli
use decreas post ici tki introduct upon failur ici tki
survey oncologist like move patient tki therapi
specif cabometyx consequ see larg neg impact
ici tki combin present scenario analysi support view
vs howev new ici tki combin keytruda inlyta
bavencio inlyta seen potenti threat outperform rate base
continu cabometyx growth rcc survey us oncologist
treat averag rcc patient per month studi rcc prescript pattern
cabometyx use rcc current pre ici tki approv predominantli
ms among system agent exhibit
match nccn guidelin survey doctor prescrib predominantli tki
follow failur ici cabometyx ms first-choic agent market
model adjust lead small chang pt
front-lin cabometyx use decreas post introduct ici tki exhibit
howev much reduct cabometyx alreadi occur
introduct opdivo yervoy earlier taken togeth find
predomin cabometyx use view impact ici tki minor
base case assumpt ms reduct current
upon failur ici tki survey oncologist would like use tki therapi
exhibit specif cabometyx popular tki cabometyx
ms could doubl current exhibit cabometyx
prefer may also driven previou widespread experi
agent oral formul exhibit
present scenario analysi highlight outcom introduct ici
potenti combo cabometyx rcc outlin bear case
scenario see reaction keytruda inlyta approv last week
overreact believ cabometyx continu growth trajectori
year price histori exelixi
compani discov develop
small molecul therapeut
treatment cancer
analyst certif import disclosur see disclosur
estim cabometyx sale includ addit indic
increas plu un-risk-adjust addit
estim cometriq sale increas
collabor royalti revenu expect increas
view well posit deliv near-term top-lin
growth expans cabozantinib best-in-class
tki addit tumor type pipelin could
deliv valu sever near-term catalyst
cabo/nivo checkmat trial rcc
data basket trial
atezolizumab tecentriq solid tumor
estim sell price four experiment product
low price increas exist product would
upsid earn estim
cabometyx cometriq fail gain addit market penetr
cabometyx fail receiv fda approv addit
indic revenu could reduc
valu base dcf valuat discount rate termin valu growth rate estim peak cabometyx
sale us pipelin model risk-adjust peak cabometyx sale probabl
success risk-adjust peak dtc sale uc po
estim growth next five year depend heavili continu success cabometyx cometriq genentech
success partner product cotel unforese reason includ competit patient behavior physician adopt loss
patent protect structur chang healthcar market penetr product could stall therebi diminish contribut
sale ep
us cabometyx sale us sale yoy
growth growth driven rcc
survey oncologist focus treatment rcc
conduct survey us oncologist treat averag rcc
patient per month averag ten new patient per month believ
doctor high-volum subscrib cabometyx averag
patient treat survey doctor classifi
advanced/metastat diseas survey doctor experi cabometyx
goal understand use cabometyx rcc estim impact
approv checkpoint inhibitor combin tki
takeaway survey
cabometyx use rcc current predominantli ms
among system agent exhibit
use cabometyx decreas post introduct ici tki
combin exhibit howev much reduct
cabometyx alreadi occur introduct opdivo yervoy
upon failur ici tki survey oncologist like move
patient tki therapi exhibit specif cabometyx
popular tki set cabometyx ms
could doubl current exhibit
prefer cabometyx may driven efficaci
data also previou widespread experi agent oral
consequ see larg neg impact cabometyx rcc
sale introduct ici tki combin keytruda
hypothet sotp valuat show cabometyx rcc
outlin bear case scenario valu would chang
see reaction keytruda inlyta approv last week
decreas pt due adjust rcc
market model specif lower progress rate
exhibit rcc patient treat survey oncologist
stage iv diseas requir system treatment half
treat patient receiv first-lin therapi quarter
treat subsequ set
exhibit survey oncologist rank factor influenc choic
system treatment interestingli rout administr
previou experi afford seem import
efficaci measur toler view import
tki oral treatment light entri combin therapi
associ higher cost
stage i-iii local stage iv first-lin therapi favor risk group stage iv first-lin therapi poor/intermedi risk group stage iv subsequenttherapi requir intervent withpharmaceut agent care treatment responserateefficaci treatment progression-fre surviv efficaci treatment overall-fre surviv os side-effect profileprevi experi therapyor vs iv treatmentaffordabilityimportancemost importantleast import exelixi
current prescript pattern clear-cel rcc
cabometyx use post checkpoint inhibitor
use may increas upon introduct
ici tki combin
exhibit current front-lin therapi choic survey oncologist
prior approv immun checkpoint inhibitor ici tki combin
clear-cel rcc favor risk group survey doctor prescrib
predominantli two tki votrient sutent
combin opdivo yervoy poor/intermedi risk
cabometyx votrient prescript pattern
stage iv first-lin therapi favor risk stage iv first-lin therapi poor/intermedi risk group outperform
survey oncologist prior approv immun checkpoint
inhibitor ici tki combin clear-cel rcc survey doctor
prescrib predominantli tki cabometyx first-choic agent
follow votrient inlyta sutent checkpoint
inhibitor also play import role opdivo monotherapi
opdivo yervoy keytruda monotherapi
prescript pattern match nccn guidelin except use
keytruda
exhibit prescript choic survey oncologist match nccn
guidelin first-lin clear-cel rcc valid respons survey
exhibit subsequ line therapi choic post front-lin failur
checkpoint inhibitor survey oncologist clear-cel rcc survey
doctor prescrib predominantli tki follow failur immun
checkpoint inhibitor ici cabometyx first-choic agent
use increas cabometyx use subsequ line
follow treatment yellow box valid exel claim
cabometyx tki choic post immun checkpoint inhibitor
exhibit expect cabometyx sale growth primarili ici tki
ici combin use frequent cabometyx
alreadi prefer tki opdivo yervoy
refractori patient receiv cabometyx accord
potenti impact prescript pattern clear-
cell rcc post approv ici tki
cabometyx use decreas use increas
exhibit view result phase
trial investig keytruda pembrolizumab combin inlyta
axitinib first-lin treatment advanc renal cell carcinoma
half survey doctor view combin keytruda inlyta
superior current soc set survey indic
current soc rcc opdivo yervoy ici therapi term tki
votrient sutent cabometyx
enough data present date influenc practicesuperior current first-lin treatment would typic use consid option upon approvalmainli replac current immunotherapi option yervoy ipilimumab opdivo nivolumab infirst-lin superior current first-lin treatment would typic use consid option upon approvalmainli replac current tki tyrosine-kinas inhibitor option votrient sutent cabometyx inlyta first-lin compar current first-lin treatment would typic use major impact choic first-lin treatmentsinferior current first-lin treatment would typic use major impact choic first-linetreat exelixi
exhibit view result javelin renal trial
investig combin bavencio avelumab inlyta
axitinib first-lin treatment advanc renal cell carcinoma
half survey doctor view combin bavencio inlyta
superior current soc set survey indic
current soc rcc opdivo yervoy ici therapi term tki
votrient sutent cabometyx interestingli bavencio inlyta seem
less popular compar opdivo yervoy
enough data present date influenc practicesuperior current first-lin treatment would typic use consid option upon approvalmainli replac current immunotherapi option yervoy ipilimumab opdivo nivolumab infirst-lin superior current first-lin treatment would typic use consid option upon approvalmainli replac current tki tyrosine-kinas inhibitor option votrient sutent cabometyx inlyta first-lin compar current first-lin treatment would typic use major impact choic first-lin treatmentsinferior current first-lin treatment would typic use major impact choic first-linetreat outperform
exhibit reduc use cabometyx cabozantinib
first-lin therapi renal cell carcinoma approv yervoy
ipilimumab opdivo nivolumab anticip reduc use
cabometyx cabozantinib first-lin therapi upon potenti approv
keytruda pembrolizumab inlyta axitinib bavencio avelumab
inlyta axitinib believ impact use cabometyx first-
line therapi modest sinc much alreadi occur
introduct opdivo yervoy survey
oncologist continu use cabometyx
yervoy ipilimumab opdivo nivolumab potenti approv keytruda pembrolizumab inlyta axitinib typic use cabometyx cabozantinib first-lin anyway not/wil reduc cabometyx cabozantinib use first-lin exelixi
exhibit combin checkpoint inhibitor tki tyrosine-
kinas inhibitor keytruda pembrolizumab inlyta axitinib
bavencio avelumab inlyta axitinib approv renal cell
carcinoma would use subsequ therapi upon
progress follow progress ici tki survey oncologist
would like use tki subsequ line therapi discuss
exhibit primari choic would cabometyx
exhibit set current use cabometyx cabozantinib
often indic exhibit cabometyx use
rcc use half survey oncologist
use cabometyx expect cabometyx use declin
line therapi follow tki tyrosine-kinas inhibitor failur first-linefirst-lin therapi favor risk group first-lin therapi poor/intermedi risk group subsequ line therapi follow checkpoint inhibitor failur decreaseexpect increaseremain constantanticip chang usag cabometyx exelixi
scenario analysi upon uptak ici tki
combin rcc
exhibit scenario analysi upon uptak ici tki combin
cabometyx use current
thereaft base data survey also model peak ms
potenti combin cabometyx opdivo trial
risk-adjust success believ achiev peak sale
rcc also present bear case scenario
cabometyx rcc sale monotherapi ici combo lost ici tki
combin scenario peak rcc sale still reach
present bull case includ opdivo cabometyx becom
combin choic rcc treatment consequ see
larg neg impact cabometyx rcc sale introduct
ici tki combin keytruda inlyta
case opdivo combo becom lead combo case forecast ms reduc current po combo case rcc sale disapear case opdivo combo becomeslead combo rcc base case forecast ms reduc current po combo withopdivo bear case rcc sale disapear outperform
exhibit hypothet sotp valuat show cabometyx
rcc outlin bear case scenario valu would chang
see reaction keytruda inlyta approv last week
overreact
drug/indicationexpect launchpeak sale estim mm unadjust npv valueest probabl successp-adj npv mm p-adj valu sharebear case sceneario rcccabometyx cometriq ici tki equiti share outstand use valuat oppenheim co
exhibit dcf valuat pt
discount except per-shar data thousand except per-shar data revenu growth chang work chang work capit valu growth valu oppenheim valu per sharetermin valu growth rateequ valu per shareprob success cabozantinib probabl cabozantinib dtc outperform
probabl success
probabl success
collabor revenu mileston
good
royalti revenu
research devleop
adjust research develop non-gaap
share-bas compens
total share-bas compenst
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compenst
total share-bas compens exclud non-gaap
total non-oper income/ expens
earn tax loss
stock price compani mention report close
